LONA Stock Forecast: LeonaBio, Inc. Price Predictions for 2026-2027

Last close, 19 Nov 2026
$2.46
−7.17% on the day

The median 12-month analyst price target for LeonaBio, Inc. is $16. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 25 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$32.2M
Ticker Nerd rank
25/ 100
Median analyst target
$16
Analysts covering
4
Revenue$0.0
Operating income−$19.3M
Net income−$19.0M
Free cash flow−$17.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−34.0%
1M
−51.3%
YTD
−67.5%
1Y
−48.3%
From 52W high
−78.9%
From 52W low
0.0%
$2
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores LeonaBio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
25/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
86
Momentum
66
Issuance
39
Volatility
29
Revisions
21
Quality
18
Value
16
Growth
11

Accruals (86): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (11): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

LONA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LONA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20Jan 26Apr 26Jul 26Oct 26LONAHigh $20Median $16Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4
Buy
0
Hold
0
Sell
$12
Low
$16
Median
$20
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 9 moved it down.

DateFirmActionRatingTarget
19 Nov 2026MizuhoMaintainsOutperform$13 → $12
17 Nov 2026CitizensMaintainsMarket Outperform$17 → $16
19 Aug 2026MizuhoMaintainsOutperform$16 → $15
17 Aug 2026CitizensMaintainsMarket Outperform$18 → $17
30 July 2026CitizensUpgradeMarket Outperform$18
27 May 2026Piper SandlerInitiatesOverweight$20
19 Feb 2026MizuhoUpgradeOutperform—
19 Sept 2024MizuhoDowngradeNeutral$5.00 → $0.50
4 Sept 2024BTIGDowngradeNeutral—
4 Sept 2024JMP SecuritiesDowngradeMarket Perform—
19 Aug 2024Rodman & RenshawInitiatesBuy$22
20 June 2024JMP SecuritiesReiteratesMarket Outperform$19
16 May 2024JMP SecuritiesReiteratesMarket Outperform$19
11 Aug 2023JMP SecuritiesMaintainsOutperform$20 → $19
15 May 2023MizuhoMaintainsBuy$6.00 → $5.00
30 Mar 2023BTIGMaintainsBuy$33 → $10
24 Mar 2023JMP SecuritiesReiteratesMarket Outperform$20
7 July 2022MizuhoInitiatesBuy$6.00
23 June 2022JefferiesDowngradeHold$32 → $3.00
23 June 2022JMP SecuritiesDowngradeMarket Perform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for LONA.

Market Radar

This page is one stock. Monday covers all of them.

LONA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

LONA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 19 Nov 2026, LeonaBio, Inc. returned −48.3% against +9.2% for the S&P 500, dividends included.

LONA vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200250Jan 26Apr 26Jul 26Oct 26LONAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

LONA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
1.5×

Cheaper than 54% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−729.0%

Higher than 2% of US stocks

Return on assets
−127.9%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • LeonaBio, Inc. has a market value of $32.2M and an enterprise value of $318K.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$141.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$61.9M.

  • Shares outstanding: 9.4M.

  • LeonaBio, Inc. employs 19 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

LONA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LONALeonaBio, Inc.$32.2M25
EYPTEyePoint, Inc.$26.6M21
TELOTelomir Pharmaceuticals, Inc.$26.8M27
KLRSKalaris Therapeutics, Inc.$26.8M27
EXOZeXoZymes, Inc.$27.0M11
EDSAEdesa Biotech, Inc.$27.0M49
INMBINmune Bio, Inc.$25.6M38

Take a look at LONA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own LeonaBio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about LONA

What is the LONA stock price forecast for 2026-2027?

The median 12-month analyst price target for LeonaBio, Inc. is $16, with estimates ranging from $12 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LONA stock a buy right now?

Of the 4 analysts covering LeonaBio, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks LeonaBio, Inc. 25 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LONA?

As at 21 Nov 2026, LeonaBio, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (86 of 100).

Will LONA stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts is $16, and Ticker Nerd's factor model ranks LeonaBio, Inc. 25 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LONA stock forecast for 2030?

No analyst covering LeonaBio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LONA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $20 over the next 12 months.

How has LONA stock performed over the past year?

LeonaBio, Inc. returned -48.3% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does LeonaBio, Inc. do?

LeonaBio, Inc. Common Stock represents the equity of LeonaBio, Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for high unmet medical needs. The company’s current pipeline centers on small-molecule treatments designed to restore neuronal health and address neurodegenerative conditions, including amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease, as well as programs in oncology such as treatment-resistant metastatic breast cancer.

Company

About LeonaBio, Inc.

LeonaBio, Inc. Common Stock represents the equity of LeonaBio, Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for high unmet medical needs. The company’s current pipeline centers on small-molecule treatments designed to restore neuronal health and address neurodegenerative conditions, including amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease, as well as programs in oncology such as treatment-resistant metastatic breast cancer. LeonaBio also works on therapies for related neurological and neuropathic disorders, with several candidates in clinical development and early-stage research. Headquartered in Bothell, Washington, LeonaBio serves the biotechnology market through a portfolio aimed at advancing drug candidates from preclinical studies into human trials, making its common stock a way to track a company positioned at the intersection of neuroscience and precision therapeutics.

CEO Dr. Mark J. Litton M.B.A., Ph.D. · 19 employees · United States · https://www.leonabio.com